172 related articles for article (PubMed ID: 27858714)
21. Exploring Alzheimer molecular pathology in Down's syndrome cerebrospinal fluid.
Portelius E; Soininen H; Andreasson U; Zetterberg H; Persson R; Karlsson G; Blennow K; Herukka SK; Mattsson N
Neurodegener Dis; 2014; 14(2):98-106. PubMed ID: 24992945
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic.
Duits FH; Prins ND; Lemstra AW; Pijnenburg YA; Bouwman FH; Teunissen CE; Scheltens P; van der Flier WM
Alzheimers Dement; 2015 May; 11(5):523-32. PubMed ID: 25156643
[TBL] [Abstract][Full Text] [Related]
23. Consensus guidelines for lumbar puncture in patients with neurological diseases.
Engelborghs S; Niemantsverdriet E; Struyfs H; Blennow K; Brouns R; Comabella M; Dujmovic I; van der Flier W; Frölich L; Galimberti D; Gnanapavan S; Hemmer B; Hoff E; Hort J; Iacobaeus E; Ingelsson M; Jan de Jong F; Jonsson M; Khalil M; Kuhle J; Lleó A; de Mendonça A; Molinuevo JL; Nagels G; Paquet C; Parnetti L; Roks G; Rosa-Neto P; Scheltens P; Skårsgard C; Stomrud E; Tumani H; Visser PJ; Wallin A; Winblad B; Zetterberg H; Duits F; Teunissen CE
Alzheimers Dement (Amst); 2017; 8():111-126. PubMed ID: 28603768
[TBL] [Abstract][Full Text] [Related]
24. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
[TBL] [Abstract][Full Text] [Related]
25. A dedicated lumbar puncture clinic: performance and short-term patient outcomes.
Barreras P; Benavides DR; Barreras JF; Pardo CA; Jani A; Faigle R; Bahouth MN
J Neurol; 2017 Oct; 264(10):2075-2080. PubMed ID: 28836071
[TBL] [Abstract][Full Text] [Related]
26. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
[TBL] [Abstract][Full Text] [Related]
27. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L
Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736
[TBL] [Abstract][Full Text] [Related]
28. Alzheimer's disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology.
Rembach A; Evered LA; Li QX; Nash T; Vidaurre L; Fowler CJ; Pertile KK; Rumble RL; Trounson BO; Maher S; Mooney F; Farrow M; Taddei K; Rainey-Smith S; Laws SM; Macaulay SL; Wilson W; Darby DG; Martins RN; Ames D; Collins S; Silbert B; Masters CL; Doecke JD;
Alzheimers Res Ther; 2015 Nov; 7(1):71. PubMed ID: 26581886
[TBL] [Abstract][Full Text] [Related]
29. Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome.
Englund H; Annerén G; Gustafsson J; Wester U; Wiltfang J; Lannfelt L; Blennow K; Höglund K
Dement Geriatr Cogn Disord; 2007; 24(5):369-74. PubMed ID: 17914261
[TBL] [Abstract][Full Text] [Related]
30. Safety and Feasibility of Research Lumbar Puncture in Huntington's Disease: The HDClarity Cohort and Bioresource.
Rodrigues FB; Owen G; Sathe S; Pak E; Kaur D; Ehrhardt AG; Lifer S; Townhill J; Schubert K; Leavitt BR; Guttman M; Bang J; Lewerenz J; Levey J; ; Sampaio C; Wild EJ
J Huntingtons Dis; 2022; 11(1):59-69. PubMed ID: 35253773
[TBL] [Abstract][Full Text] [Related]
31. Inositol monophosphatase activity in normal, Down syndrome and dementia of the Alzheimer type CSF.
Atack JR; Schapiro MB
Neurobiol Aging; 2002; 23(3):389-96. PubMed ID: 11959401
[TBL] [Abstract][Full Text] [Related]
32. An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter.
Lucey BP; Gonzales C; Das U; Li J; Siemers ER; Slemmon JR; Bateman RJ; Huang Y; Fox GB; Claassen JA; Slats D; Verbeek MM; Tong G; Soares H; Savage MJ; Kennedy M; Forman M; Sjögren M; Margolin R; Chen X; Farlow MR; Dean RA; Waring JF
Alzheimers Res Ther; 2015; 7(1):53. PubMed ID: 26225140
[TBL] [Abstract][Full Text] [Related]
33. [Diagnostic lumbar puncture performed in the outpatient setting of a memory clinic. Frequency and risk factors of post-lumbar puncture headache].
Popp J; Riad M; Freymann K; Jessen F
Nervenarzt; 2007 May; 78(5):547-51. PubMed ID: 17160541
[TBL] [Abstract][Full Text] [Related]
34. Where there is no brain imaging: Safety and diagnostic value of lumbar puncture in patients with neurological disorders in a rural hospital of Central Africa.
Mukendi D; Kalo JL; Kayembe T; Lutumba P; Barbé B; Gillet P; Jacobs J; Yansouni CP; Chappuis F; Verdonck K; Boelaert M; Winkler AS; Bottieau E
J Neurol Sci; 2018 Oct; 393():72-79. PubMed ID: 30121441
[TBL] [Abstract][Full Text] [Related]
35. Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease.
Zimetti F; Caffarra P; Ronda N; Favari E; Adorni MP; Zanotti I; Bernini F; Barocco F; Spallazzi M; Galimberti D; Ricci C; Ruscica M; Corsini A; Ferri N
J Alzheimers Dis; 2017; 55(1):315-320. PubMed ID: 27662294
[TBL] [Abstract][Full Text] [Related]
36. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.
Kester MI; Teunissen CE; Sutphen C; Herries EM; Ladenson JH; Xiong C; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
Alzheimers Res Ther; 2015 Sep; 7(1):59. PubMed ID: 26383836
[TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal fluid production is normal in Down syndrome.
Atack JR; Rapoport SI; Schapiro MB
Neurobiol Aging; 1998; 19(4):307-9. PubMed ID: 9733162
[TBL] [Abstract][Full Text] [Related]
38. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
39. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
[TBL] [Abstract][Full Text] [Related]
40. Ex vivo lumbar and post mortem ventricular cerebrospinal fluid substance P-immunoreactivity in Alzheimer's disease patients.
Rösler N; Wichart I; Jellinger KA
Neurosci Lett; 2001 Feb; 299(1-2):117-20. PubMed ID: 11166952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
